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Tumornecrosisfactor-relatedapoptosis-inducingligand(TRAIL)iscurrentlybeinginvestigatedasatherapeuticagentforavariety
of malignancies, as it triggers apoptosis speciﬁcally in transformed cells. However, TRAIL use as a stand alone therapeutic is
hampered by the fact that many primary tumor cells are resistant to TRAIL-mediated apoptosis. Here, we investigated the extent
to which pretreatment of TRAIL-resistant primary B-cell chronic lymphocytic leukemia (B-CLL) cells with histone deacetylase
inhibitors (HDACis) could render them susceptible to killing by TRAIL. We found that HDAC inhibition in B-CLL cells led to
increased TRAIL receptor expression, increased caspase activation, decreased expression of antiapoptotic regulators such as Bcl-2,
and ultimately, enhanced TRAIL-induced apoptosis. Importantly, untransformed peripheral blood mononuclear cells remained
largely resistant to TRAIL, even in the presence of HDACis. These results suggest that combination therapies using HDAC
inhibition and TRAIL could prove beneﬁcial for the treatment of B-CLL.
Copyright © 2009 Lyse A. Norian et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Inducing apoptosis in tumor cells is a promising therapeutic
approach for the treatment of both solid and lymphatic
tumors. The TNF family member tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL) is an apoptotic
mediator that has received much attention, due to its
ability to bring about cell death speciﬁcally in tumor
cells without aﬀecting untransformed cells or tissues [1–3].
In humans, TRAIL interaction with either of two death-
domain containing receptors, TRAIL-R1 (DR4) or TRAIL-
R2 (DR5), leads to apoptosis in target cells [4–7]. Death
receptor ligation activates the extrinsic apoptosis pathway
and results in recruitment of FADD and caspase 8 to
the death-inducing signaling complex (DISC), followed by
activation of caspase 8 and caspase 3 [8–12]. This type of
apoptosis diﬀers mechanistically from that brought about
by the cell intrinsic pathway, which is mediated by early
activation of caspase 9, and leads to loss of mitochondrial
membrane potential [13, 14]. Both TRAIL-R1 and -R2 have
been found on a wide variety of primary tumor cells and
tumor cell lines, making TRAIL-induced apoptosis ideal
for therapeutic intervention in a number of malignancies.
Equally important, recombinant soluble TRAIL protein has
shown no toxicity in Phase I clinical trials [15] highlighting
itssafetyasatherapeuticagent.Despitethispotential,TRAIL
use as a stand-alone therapeutic has been hampered by the
fact that many primary tumor cells are inherently resistant to
TRAIL-mediated apoptosis, despite expressing extracellular
TRAIL receptors [16].
B-cellchroniclymphocyticleukemia(B-CLL)isthemost
frequent type of leukemia found in western countries [17]. It
is characterized by an accumulation of mature, nonprolifer-
ating B lymphocytes in the blood, spleen, lymph nodes and
bone marrow. The accumulation of B-cells results not from
a proliferative defect, but rather from a failure of B-cells to
undergo apoptosis, leading to large numbers of cells blocked
in the G0/G1 phase of the cell cycle [18]. Not surprisingly,2 Journal of Oncology
then, prior studies have shown that B-CLL cells are resistant
to TRAIL-induced apoptosis [19]. The reasons for this are
unclear, but may include a combination of the following:
reduced expression of the death-inducing receptors TRAIL
-R1 and -R2, reduced expression of downstream caspase 8,
or overexpression of antiapoptotic molecules such as FLIP.
To circumvent this inherent resistance to TRAIL-mediated
apoptosis, we sought to determine the extent to which using
TRAIL in combination with histone deacetylase inhibitor
(HDACi) administration could bring about apoptosis in
primary B-CLL cells.
HDACi are a promising group of anticancer agents
that have been used successfully alone or in combination
to induce tumor cell death in vitro and in vivo [20,
21]. HDACi function by regulating chromatin structure,
leading to the transcription of genes that are normally
repressed during tumor outgrowth. In normal cells, chro-
matin structure is tightly regulated by the contradictory
actions of two enzymes. Histone acetyltransferases (HATs)
add acetyl groups to lysine residues on histone tails that
protrude from compacted nucleosome structures [22]. This
leads to a relaxation and an opening of the chromatin
structure, allowing transcription factors to bind, and gene
transcription to occur. HAT function is counteracted by
HDACs, enzymes that remove acetyl groups, thereby causing
a recompaction of the nucleosomes, and a silencing of gene
transcription. By preventing histone deacetylation, HDACi
maintain chromatin in an open structure [23]. Because
many tumors overexpress HDACs, normal transcription of
genes, including tumor suppressor genes, is suppressed.
Treatment of tumor cells with HDACis counteracts this
abnormalityandresultsinanetinhibitionoftumorcellcycle
progression, and induction of either or both of the intrinsic
and extrinsic apoptotic pathways, depending on the type of
tumor cell being studied. HDACis also have eﬀects that are
independent of histone de-acetylation, including acetylation
ofnonhistoneproteinssuchasp53,Rb,andhsp90,induction
of p21 with consequent cell cycle arrest, and generation of
oxidative stress via production of reactive oxygen species
[24]. At present, 11 diﬀerent HDACs have been identiﬁed,
grouped into 4 families, and HDACi may target one or
more of these molecules, depending upon their structure
[24]. Additionally, HDACis have proven to be nontoxic to
untransformed cells, leading to their recent use in a number
of clinical trials.
Based on previous studies by our group and others, in
which the combination of HDACi and TRAIL was able to
bring about apoptosis of tumor cells that were resistant to
single therapy with either agent alone [25–30], we sought
to examine the use of HDACi and TRAIL as a potential
combination therapy for B-CLL. We examined a panel of
HDACi for their ability to upregulate TRAIL-R1 and -R2 on
B-CLL cells from cancer patients, and to sensitize those cells
to TRAIL-mediated apoptosis. We found that use of either
Oxamﬂatin (Oxam) or Trichostatin A (TSA), two hydrox-
amic acid-based HDACis, sensitized B-CLL cells to TRAIL-
mediated apoptosis, due to their ability to upregulate both
TRAIL-R1 and TRAIL-R2, increase activation of caspase 8,
and increase expression of the proapoptotic protein Bax
while decreasing expression of the antiapoptotic molecules
Bcl-xL and Bcl-2. Importantly, the combination therapies
showed limited toxicity against normal PBMC. Thus, our
study illustrates the feasibility of using HDACi and TRAIL
in combination to mediate apoptosis of B-CLL cells.
2.MaterialsandMethods
2.1. Reagents and Antibodies. The HDACi Trichostatin A
(resuspended in EtOH) was purchased from Sigma (St.
Louis, MO, USA); Oxamﬂatin (resuspended in DMSO) was
purchased from Calbiochem (San Diego, CA, USA). All
other HDACis are as previously described [30]. Antibodies
against TRAIL-R1 and TRAIL-R2 (eBioscience, San Diego,
CA,USA)wereusedforﬂowcytometricanalysisaccordingto
the manufacturer’s suggestions. Recombinant human TRAIL
(Peprotech,RockyHill,NC,USA)consistedofthe168amino
acid extracellular domain, and was used at the indicated
doses.
2.2. Primary Cell Preparations. Peripheral blood samples
wereobtainedfrompatientsattheUniversityofIowaHolden
Comprehensive Cancer Center who were diagnosed with
B-CLL, or from healthy control donors. Experiments were
repeated 3–5 times, using cells from diﬀerent donors. Lym-
phocytes were enriched by density gradient centrifugation
using Ficoll-Hypaque. Cells were cultured in RPMI 1640
supplemented with 10% FCS, 1% nonessential amino acids,
1mM sodium pyruvate, and 1% penicillin/streptomycin
solution. This study was conducted according to protocols
approved by the institutional review board at the University
ofIowa,andinformedconsentwasobtainedfromallpatients
before blood sample collection.
2.3. In Vitro Killing Assay. Cells were cultured in complete
medium at 2 × 104 cells/well in 96-well plates. Cells were
either cultured in medium alone or in the presence of
individual HDACi at the indicated doses, for 16 hours. After
this pretreatment, recombinant human TRAIL was added at
100ng/mL, and cells were cultured for an additional 4 hours.
Cell death was determined by costaining for Annexin V
and propidium iodide, to permit identiﬁcation of apoptotic
versus necrotic cells.
2.4. Quantitation of Caspase Activity and Mitochondrial
Membrane Potential. Brieﬂy, cells were cultured in complete
medium, in the presence or absence of individual HDACi
for 16 hours, followed by a 4 hour treatment with TRAIL as
above. Caspase activity was quantitated as described previ-
ously [30]. Brieﬂy, cells were harvested, and incubated with
ﬂuorescently labeled caspase inhibitor peptides, according to
the manufacturer’s protocol (Immunochemistry Technolo-
gies, Bloomington, MN, USA). Inhibitor peptides were as
follows: Caspase 3 = carboxyﬂuorescein- Asp-Glu-Val-Asp;
Caspase 8 = carboxyﬂuorescein- Leu-Glu-Thr-Asp; Caspase
9 = carboxyﬂuorescein- Leu-Glu-His-Asp. MMP was quan-
titated via the use of the MitoPT mitochondrial permeability
transition kit according to the manufacturer’s suggestedJournal of Oncology 3
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Figure 1:HDACinhibitionbyOxamandTSAleadstoTRAILreceptorexpressiononB-CLLcells. (a)ThepercentagesofB-CLLcellsexpressing
TRAIL-R1 or TRAIL-R2 are shown. B-CLL cells were cultured for 16 hours in the presence or absence of individual HDACi, as indicated,
then analyzed by ﬂow cytometry for TRAIL-R1 and TRAIL-R2 surface expression. Filled grey histogram = Isotype control, dotted line =
untreated, solid line = HDACi. (b) Enriched PBMC from healthy donors were cultured for 16 hours as indicated, then the surface expression
levels of TRAIL-R1 and TRAIL-R2 were analyzed by ﬂow cytometry. Filled histogram = Isotype control, dotted line = untreated, solid line
= vehicle alone or HDACi. Numbers indicate the percentages of positively staining cells, compared to isotype. (c) TRAIL-R1 and TRAIL-R2
mRNA levels in B-CLL cultured as indicated for 16 hours. (d) The percentages of B-CLL cells expressing surface TRAIL-R1 or TRAIL-R2 in
response to varying doses of TSA are given. Filled histogram = Isotype control, dotted line = untreated, solid line = vehicle alone or HDACi.
For all panels, one experiment, representative of at least 5 experiments using cells from diﬀerent donors, is shown.
protocol (Immunochemistry Technologies, Bloomington,
MN, USA).
2.5. Quantitative Reverse Transcription PCR. Total RNA was
isolated from cultured cells with Trizol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s proto-
col. Reverse transcription of total RNA was done by using
SuperscriptII.Thereal-timeqRT-PCRprimerandprobesets
were purchased from Applied Biosystems (Foster City, CA).
cDNA (250ng) was used as a template for TaqMan Assays
and the internal control of rRNA. The TaqMan reaction was
conducted as previously described [31].
3. Results
3.1. The HDACi Oxam and TSA Upregulate TRAIL Receptor
Expression on B-CLL Cells. To evaluate the potential ther-
apeutic eﬃcacy of combining HDACi with recombinant
TRAIL for the treatment of B-CLL, we began by examining
the ability of a panel of HDACi to upregulate TRAIL receptor
expression on B-CLL. Human B-CLL were cultured for 16
hours in the presence or absence of individual HDACi.
As shown in Figure 1(a), untreated B-CLL express little to
no TRAIL-R1 or TRAIL-R2. In contrast, several HDACis,
including Oxam and TSA, were ableto upregulateexpression
of both TRAIL-R1 and TRAIL-R2 on B-CLL, although the
increases in TRAIL-R1 were modest compared to those
observed for TRAIL-R2. Not all HDACis were equivalent in
their ability to upregulate TRAIL receptor expression, as MS-
275 and DEPSI had little eﬀect on TRAIL-R1 expression, yet
strongly upregulated TRAIL-R2 (Figure 1(a)).
Because we have shown previously that combination
therapy with TRAIL and HDACi can lead to TRAIL
sensitivity in untransformed cells [32], it was critical to
determine the extent to which Oxam or TSA administration
would lead to TRAIL-R1 and -R2 upregulation on normal
PBMC. PBMC were obtained from healthy donors, and were
incubated with Oxam or TSA for 16 hours. After this time,
cells were harvested and analyzed by ﬂow cytometry to assess4 Journal of Oncology
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Figure 2: HDACi treatment sensitizes B-CLL cells to TRAIL-induced apoptosis. (a) B-CLL cells were cultured with or without 2.5μMO x a mo r
500ng/mlTSAorvehiclealonefor16hoursbeforeadditionof100ng/mlrhTRAIL.Cultureswereharvested4hourslater,andthepercentage
of cells undergoing apoptosis was determined by Annexin V staining. One experiment, representative of more than 5 experiments using cells
from diﬀerent donors, is shown. (b) The mean percentage of Annexin V
+/PI
− cells is shown for each treatment group. Cells were cultured
as in (a).
whether TRAIL-R1 and/or TRAIL-R2 surface proteins were
upregulated. Untreated PBMC from healthy donors did not
express TRAIL -R1 or -R2, and neither Oxam nor TSA
caused increased expression of these proteins (Figure 1(b)).
To assess whether the upregulated surface expression
of TRAIL-R1 and TRAIL-R2 on B-CLL cells was due to
changes in the quantity of mRNA present, we cultured cells
for 16 hours in the absence or presence of varying doses of
Oxam or TSA. Both Oxam and TSA were found to increase
mRNA levels of TRAIL- R2 (Figure 1(c)), suggesting that
these compounds were acting to promote gene transcription.
In contrast, Oxam did not elevate TRAIL-R1 mRNA levels
over untreated controls, indicating that a transcription-
independent mechanism was responsible for the upregu-
lation of TRAIL-R1 surface expression. Some experiments
actually showed a decrease in TRAIL-R1 mRNA levels in
the presence of Oxam versus untreated controls, which
could suggest that Oxam was decreasing transcription or
altering the half-life of TRAIL-R1 mRNA in those instances.
While the 500ng/mL dose of TSA led to clear enhancement
of TRAIL-R1 and -R2 protein expression, lower doses
failed to reproducibly aﬀect TRAIL-R1 surface expression
(Figure 1(d)). Therefore, speciﬁc doses of 2.5uM Oxam and
500ng/mL TSA were used for all subsequent experiments.
Collectively, these results show that Oxam and TSA induce
transformed B-CLL, but not normal PBMC, to upregu-
late TRAIL-R1 and TRAIL-R2 surface expression, through
transcription-dependent and independent mechanisms.
3.2. Treatment with HDACi Sensitizes B-CLL Cells to TRAIL-
Induced Apoptosis. Once we had determined that Oxam
and TSA upregulated TRAIL receptor expression on B-CLL
cells, we then determined whether this translated into an
increase in susceptibility to TRAIL-mediated apoptosis. B-
CLL cells were again cultured alone (untreated) or in the
presence of 2.5μM Oxam or 500ng/mL TSA for 16 hours
prior to the addition of recombinant TRAIL at 100ng/ml.Journal of Oncology 5
Cultures were harvested 4 hours later, and the percentage of
TRAIL-induced apoptosis measured by Annexin V staining.
As controls, normal PBMCs were cultured simultaneously.
In agreement with previous reports [19, 33, 34], we found
that untreated B-CLL were resistant to killing by TRAIL
alone (Figures 2(a) and 2(b), <10% cell death). The addition
of either Oxam or TSA in the absence of TRAIL caused
only minimal increases in B-CLL apoptosis (mean = 15%
and 18%, resp.). In contrast, when recombinant TRAIL was
a d d e da f t e re i t h e rO x a mo rT S Ap r e t r e a t m e n t ,r o u g h l ya
third of B-CLL cells became apoptotic within the 4 hours
TRAIL incubation period. Importantly, PBMC from healthy
donors were much less susceptible to TRAIL-mediated
killing, even in after pre-incubation with Oxam or TSA
(mean = 18% and 12%, resp.). The majority of the cell
death observed in PBMC was due to the actions of TSA or
Oxam, rather than the addition of TRAIL (compare PBMCs
with TSA alone versus TSA+TRAIL). To determine whether
longer incubations with HDACi alone would cause greater
percentagesof cells to undergo apoptosis, we cultured B-CLL
cells or PBMC alone or in the presence of Oxam or TSA for
24 or 48 hours. However, the percentages of cells undergoing
apoptosis remained similar to those shown in Figure 2(b)
(data not shown). Therefore, the HDACi Oxam and TSA
preferentially sensitize B-CLL to TRAIL-mediated apoptosis,
as compared to normal PBMCs.
3.3. TRAIL-Mediated Caspase Activation Is Enhanced by
the Presence of HDACi. We next wanted to determine the
mechanism by which Oxam and TSA sensitized B-CLL
cells to TRAIL-mediated killing. TRAIL induces apoptosis
via activation of downstream caspases, including caspase
8, and this signal can be augmented by the loss of mito-
chondrial membrane potential (MMP). B-CLL cells were
again cultured in the presence or absence of either Oxam or
TSA for approximately 16 hours, followed by culture with
recombinant TRAIL. Preculture of cells with Oxam or TSA
led to striking increases in the activity of caspases 8, 9, and
3 after TRAIL administration (Figure 3(a)). As expected, the
activity of all three caspases remained low when Oxam, TSA
or TRAIL were used individually.
Both capsases 8 and 3 are activated during the extrinsic
apoptosis pathway, whereas caspase 9 is associated with the
intrinsic apoptosis pathway [35]. Triggering of the intrinsic
pathway leads to a loss of MMP and release of cytochrome
C, which allows cytochrome C to then interact with Apaf
1 and procaspase 9, eventually resulting in active caspase 9
[36]. Because caspase 9 activity was increased after B-CLL
treatment with HDACi and TRAIL, this suggested that cells
were also experiencing a loss of MMP. In fact, when we
examined B-CLL for a loss of MMP, we found that pre-
treatment with HDACi followed by TRAIL administration
increased the percentage of cells exhibiting a loss in MMP
(Figure 3(b)). This was not observed in B-CLL treated with
either HDACi or TRAIL alone. Thus, both the extrinsic
and intrinsic apoptotic pathways are initiated in B-CLL cells
treated with the combination of HDACi and TRAIL.
C
a
s
p
a
s
e
a
c
t
i
v
e
c
e
l
l
s
(
%
) 40
30
20
10
0
Oxam TSA TRAIL Oxam +
TRAIL
TSA +
TRAIL
Caspase 8
Caspase 9
Caspase 3
(a)
C
e
l
l
s
w
i
t
h
M
M
P
l
o
s
s
(
%
) 100
80
60
40
20
0
Medium DMSO EtOH Oxam TSA
Medium
TRAIL (100ng/ml)
(b)
Figure 3: HDACi pretreatment leads to increased caspase activity
and MMP loss with TRAIL administration. (a) B-CLL cells were
cultured in the presence or absence of 2.5μM Oxam or 500ng/ml
TSA for 16 hours, followed by a 6 hours incubation with rhTRAIL
(100ng/ml). At that time, cells were harvested, and their caspase
activity was determined as described in the Methods. (b) B-CLL
cells were cultured in the presence or absence of 2.5μMO x a m
or 500ng/ml TSA for 16 hours, followed by a 6 hour incubation
with or without rhTRAIL at 100ng/ml. Mitochondrial membrane
potential was assayed as described in the Methods. One experiment
each, representative of more than 5 experiments using cells from
diﬀerent donors, is shown.
The preceding experiments indicated that HDACi pre-
treatment sensitized B-CLL cells to subsequent apoptosis
with TRAIL. Mechanistically, this appeared to result from
a variety of factors, including enhanced TRAIL receptor
expression, increased caspase activation, and loss of MMP.
Additional mechanisms of sensitization could also include
activation of pro-apoptotic regulators and inhibition of
antiapoptotic molecules. To determine if these factors were
also contributing to elevated TRAIL-mediated apoptosis
following HDACi treatment, we examined changes in apop-
totic regulators at the mRNA level. As before, B-CLL cells
w e r et r e a t e dw i t he i t h e rO x a mo rT S Af o r1 6h o u r s ,
t h e ne x a m i n e df o rc h a n g e si nm R N Al e v e l so fs e v e r a lk e y
apoptotic regulators. Both Oxam and TSA led to modest
increases in mRNA for the pro-apoptotic molecule Bax, but6 Journal of Oncology
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Figure 4: HDAC inhibition prior to TRAIL administration primes
cells for death via alterations in levels of apoptotic regulators. B-CLL
cells were cultured with or without 2.5μM Oxam or 500ng/ml
TSA for 16 hours prior to cell harvest and RNA preparation. (a)
The fold change in mRNA levels for the indicated pro-apoptotic
regulators is shown. (b) The fold change in mRNA levels for the
indicated antiapoptotic regulators is shown. One experiment each,
representative of more than 5 experiments using cells from diﬀerent
donors, is shown.
substantial increases for the pro-apoptotic molecule Mcl-1
short, resulting in a 13-fold increase in mRNA levels with
TSA treatment (Figure 4(a)). At the same time, both Oxam
and TSA produced sharp decreases in mRNA levels for
the antiapoptotic molecules Bcl-2 and Bcl-xL (Figure 4(b)).
Therefore, the HDACi Oxam and TSA sensitized B-CLL cells
to TRAIL-mediated apoptosis by both increasing levels of
pro-apoptotic regulators and decreasing levels of molecules
that normally protect cells from undergoing apoptosis.
4. Discussion
B-CLL is the most prevalent form of adult leukemia, and is
characterized by an accumulation of mature, often CD52+
B lymphocytes in the bone marrow and blood [17, 18].
Atpresent,treatmentoptionsforB-CLLarelimited,andpro-
gressive disease is typically fatal. Campath (alemtuzumab)
is an anti-CD52 monoclonal that targets B-CLL cells, and
is currently one of the more promising therapeutic options,
althoughresponseratesremainatlessthan40%[37].Clearly,
new treatment options are needed for these patients.
TRAIL is a promising anticancer agent, given that
it can speciﬁcally induce apoptosis in transformed cells,
without aﬀecting normal host cells or tissues [1–3]. A major
limitation of TRAIL therapy is the fact that many primary
tumor cells are inherently resistant to TRAIL-mediated
killing [16]. The reasons for this vary, but may include a lack
of expression of TRAIL receptors on tumor cells, inadequate
caspase activation after TRAIL receptor ligation, or over-
expression of antiapoptotic molecules such as Bcl-2. This
fact has led to the pursuit of TRAIL-based combination
therapies, in which TRAIL administration is combined with
other anticancer agents in an attempt to render tumor cells
susceptible to TRAIL-mediated killing.
We and others have previously explored the use of
TRAIL in conjunction with HDACi administration [25–30].
HDACis are also being pursued as anticancer therapeutics,
given that they can bring about tumor cell apoptosis by
reversing transcriptional repression. Because the modes of
action of TRAIL and HDACi are distinct, their combined use
appears to lead to synergistic killing of many tumor types
that are normally TRAIL resistant, including bladder cancer
cells, renal cell carcinomas, and prostate cancer cells [25–
30]. For example, although TRAIL and HDACi combination
therapies were shown to be successful in bringing about
apoptosis in renal cell carcinoma lines, we also observed
that combination therapies caused untransformed human
renal proximal tubule epithelial cells to become susceptible
toTRAIL-mediatedkilling[32].Therefore,thecombineduse
of two agents which by themselves do not kill untransformed
cells led to apoptosis of normal cells. This underscores the
importance of evaluating potential TRAIL-based combina-
tion therapies for their eﬀects on untransformed primary
tissues. Despite this fact, TRAIL remains one of the most
promising anticancer biologics, given that phase I clinical
trials with TRAIL alone demonstrated no toxicity [15]a n d
numerous preclinical studies have shown that TRAIL as a
stand-alone agent does not target normal cells. Thus, the
challenge is to ﬁnd doses and combinations of agents that
render TRAIL- resistant tumor cells susceptible to TRAIL-
mediated killing, while sparing normal host tissues from
toxic side eﬀects.
In this study, we found that pretreatment of primary
B-CLL cells with either of two HDACis, Oxam, or TSA,
led to upregulated TRAIL receptor expression, increased
caspase 8 activation, triggered a loss of MMP, and decreased
expression of antiapoptotic regulators such as Bcl-2. The net
result was a signiﬁcant increase in TRAIL-mediated killing
of B-CLL cells, such that over 30% of B-CLL cells became
Annexin-V+ during the 4 hours TRAIL incubation period.
This is in comparison to B-CLL cells treated with TRAIL
alone, which produced apoptosis in fewer than 10% of cells.
This reversal in susceptibility to TRAIL-mediated apoptosis
indicates the eﬃcacy of B-CLL pretreatment with HDACi.Journal of Oncology 7
Importantly, normal PBMCs were much more resistant to
the combination of HDACi + TRAIL, suggesting that this
typeoftherapymayhaveapplicabilityinB-CLLpatients.The
combination of Oxam + TRAIL produced less apoptosis in
normal PBMC than did TSA + TRAIL, which indicates that
it may be possible to modify the timecourse or dose of agents
in vivo to further limit killing of untransformed cells.
Our observations extend work by Garofalo et al. in
which they examined the role of PED, an antiapoptotic
molecule, as a mechanism for B-CLL resistance to TRAIL-
mediated killing [33]. In that study, the authors found that
B-CLL cells treated with PED antisense oligonucleotides,
protein synthesis inhibitors, or the HDACi valproic acid or
TSA could downregulate PED expression, rendering B-CLL
cells susceptible to TRAIL killing. Interestingly, the authors
concluded that treatment of B-CLL cells with TSA did not
alter the expression of other antiapoptotic molecules such
as Bcl-2, nor did it increase expression levels of TRAIL-
R1 and TRAIL-R2. In contrast, we ﬁnd that a ﬁve-fold
higher dose of TSA (500ng/ml) does lead to increased
mRNA levels for TRAIL-R1 and TRAIL-R2, does upregulate
surface expression of these same receptors, and does cause
Bcl-2 mRNA levels to decrease substantially. These ﬁndings
highlight the importance of dose eﬀects, even with the same
anticancer agents, and reveal that HDAC inhibition by TSA
aﬀects multiple pathways that culminate in B-CLL sensitivity
to TRAIL-mediated apoptosis.
5. Conclusions
We show here that pretreatment of TRAIL resistant B-CLL
cells with either of two HDACis, Oxam, or TSA, renders
cellssusceptibletosubsequentkillingbyrecombinantTRAIL
protein. Both Oxam and TSA led to increased surface
expression of TRAIL-R1 and TRAIL-R2, increased caspase
8 and caspase 3 activation, a loss of MMP, and changes in
mRNA levels for key pro- and antiapoptotic regulators, all of
which combined to sensitize B-CLL cells to TRAIL-induced
apoptosis. Importantly, combination therapies preferentially
sensitized transformed cells to apoptosis, as the same level of
killing was not observed in normal PBMC. Thus, combina-
tiontherapiesusingspeciﬁcHDACiandrecombinantTRAIL
may prove to be eﬃcacious for the treatment of B-CLL in
humans.
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